ZANE ProEd
PharmacovigilanceStatus: PUBLISHED // Data_Point_ai-i

AI in Pharmacovigilance: What Is Automated and What Stays Human

November 22, 2026 7 min read ZANE ProEd Drug Safety Intelligence Desk
Reviewed by: Dr. Mohammed Anas, Pharm.D
AI in Pharmacovigilance: What Is Automated and What Stays Human

Searchers looking up ai in pharmacovigilance usually want a plain account of what software now does in drug safety teams and what it cannot do alone. Automation has moved into high-volume tasks such as intake and coding, while judgement about causality, seriousness and regulatory reporting remains with trained people.

How is AI used in pharmacovigilance today?

In practice, AI in pharmacovigilance sits inside existing safety databases and case workflows rather than as a separate system. Most deployed tools support one step at a time, and their output is a suggestion that a person accepts, edits or rejects.

Recommended_Programs

Build These Skills Now

Programs from ZANE ProEd Academy that directly address the skill gaps discussed above.

Browse all pharmacovigilance courses →

Common uses fall into four groups:

  • Intake triage: ranking incoming reports by likely validity and seriousness so that the most urgent items are handled first.
  • Duplicate detection: comparing new reports against existing cases on patient details, drug, event, dates and identifiers.
  • Information extraction: using natural language processing to pull drugs, events, dates and laboratory values from free text in source documents and literature.
  • Coding support: suggesting MedDRA preferred terms for reported events, which a trained coder confirms.

Data mining is an older use. The ICH E2C(R2) guideline already recognises automated data mining techniques as part of modern pharmacovigilance practice [3]. Machine learning extends these methods, but the regulatory expectation of documented evaluation stays the same.

Duplicate detection is where the rules matter most. The sender's case safety report unique identifier and the worldwide unique case identification number are defined data elements in E2B(R3), and they give a matching tool concrete fields to compare [4].

TaskWhat AI typically doesHuman checkpoint
Intake triageRanks and routes incoming reportsAssessor confirms validity and seriousness before any reporting decision
Duplicate detectionProposes likely matches to existing casesAssociate confirms, nullifies or links the case per procedure
MedDRA codingSuggests preferred terms from event textCoder verifies each term against the source document
Literature screeningFlags articles that may describe a caseReviewer decides whether minimum case criteria are met
Narrative drafting with a large language modelDrafts a case narrative from source textMedical reviewer checks every fact against the source

Will AI replace drug safety associates?

Not for the core judgement work, and the regulatory framework does not describe a model in which software carries that responsibility. Routine pharmacovigilance requires systems and processes that collect and collate information about suspected adverse reactions, and the preparation of expedited reports and periodic safety update reports [2]. Those obligations belong to the company, so the people who run those processes remain accountable.

What changes is the mix of work. Repetitive keying and first-pass sorting shrink, while validation of tool output, quality control, exception handling, system configuration and audit trail review grow. A large language model can produce fluent text that is partly wrong, so reviewers must check it against the source rather than trust its wording.

Skills that stay human include:

  • Applying the regulatory definition of an adverse drug experience and an individual case safety report to a real case [5].
  • Judging causality and whether an event is serious, using clinical context that a tool may not have.
  • Recognising when a source is ambiguous and requesting follow-up.
  • Explaining a decision in an audit trail that an inspector can follow.

Which PV tasks are being automated?

Tasks that are rule-based, high in volume and checkable against a source are the ones most often automated. Tasks that need clinical reasoning, or that create regulatory submissions without a second check, are the ones kept under close human control. Duplicate handling is a good illustration of how the two sit together.

Worked example (hypothetical case, identifiers invented for illustration):

  1. Report A arrives from a hospital sender with a case identifier, a patient reference, a suspect drug and an event of rash.
  2. Report B arrives two weeks later from the same sender, with the same patient reference, drug and event, and quotes Report A's identifier in its previous-transmission field.
  3. The tool scores the similarity and proposes Report B as a duplicate of Report A.
  4. The associate opens both source documents and checks patient identity, drug, event, dates and sender.
  5. If the duplicate is confirmed, one case is nullified and the remaining valid case is updated with any new information through a follow-up report, as the EMA GVP Module VI describes for same-sender duplicates [1].
  6. The associate records the decision and the reason in the audit trail. If the tool had been wrong, for example a different patient with similar details, the associate rejects the suggestion and logs the error for the validation team.

Automation in case processing is strongest at the front of the workflow, where volume is high and the checks are mechanical. For a view of how these steps fit into a routine case workflow, see the Pharmacovigilance Case Processing Jobs Freshers: Complete Industry Workflow Roadmap.

Signal detection is the area where AI is most often discussed and least often fully automated. Tools can rank combinations of drug and event for review, but a signal assessment still needs clinical and epidemiological judgement. The Signal Detection Pharmacovigilance Career: Recruiter POV Guide explains the skills employers look for in this area.

Key takeaways

  • AI in pharmacovigilance today mostly supports intake triage, duplicate detection, information extraction and MedDRA coding suggestions.
  • Every automated output needs a documented human check against the source document before it affects a case or a report.
  • Routine pharmacovigilance obligations remain with the company, so automation does not transfer accountability [2].
  • Duplicate handling follows defined rules for nullification and follow-up, and a tool only proposes the match [1].
  • Large language models are useful for drafting and summarising, but their output must be verified because it can be fluent and wrong.
  • The skills that stay human are clinical judgement, causality and seriousness assessment, regulatory interpretation and audit-ready documentation.

Recommended_Programs

Build These Skills Now

Programs from ZANE ProEd Academy that directly address the skill gaps discussed above.

Browse all pharmacovigilance courses →

How can I practise AI-assisted case work hands-on?

The AI-Powered Pharmacovigilance Specialist course on ZANE ProEd (10-14 days, intermediate level) gives you a place to practise AI-assisted ICSR triage, MedDRA auto-coding validation and E2B(R3) data quality checks in a simulated safety environment. Course details are at academy.zaneproed.com.

Frequently asked questions

Does AI change pharmacovigilance reporting deadlines?

No. Reporting obligations are set by the applicable regulation, not by the software used to process a case. In the United States, postmarketing reporting of adverse drug experiences is governed by 21 CFR 314.80 [5].

What is LLM drug safety?

LLM drug safety refers to using large language models for tasks such as summarising literature, drafting case narratives and answering questions about safety documents. The main risks are fabricated content and inadvertent data disclosure, so use needs source verification, restricted data handling and documented validation.

What does AI pharmacovigilance look like in 2027?

No reliable forecast exists that these sources can support. Expect assisted tasks to expand, but follow current regulatory guidance and your company's standard operating procedures, which take precedence over any tool's default behaviour.

Do I need coding knowledge to work with AI tools?

Yes, in practice. Validating an auto-coded MedDRA term requires understanding how the dictionary is structured and how the reported event text maps to it. Entry-level candidates can build this knowledge through the Pharmacovigilance Jobs for Freshers in India: Step-by-Step Roadmap.

Sources

  1. EMA Good Pharmacovigilance Practices (GVP) Module VI: Collection, management and submission of reports of suspected adverse reactions (Rev 2). EMA.
  2. ICH E2E: Pharmacovigilance Planning (Step 4 (2004)). ICH.
  3. ICH E2C(R2): Periodic Benefit-Risk Evaluation Report (PBRER) (R2). ICH.
  4. ICH E2B(R3): Electronic Transmission of Individual Case Safety Reports (ICSRs): Data Elements and Message Specification (R3). ICH.
  5. 21 CFR 314.80: Postmarketing reporting of adverse drug experiences (eCFR (current)). FDA.
Recommended_Programs

Build These Skills Now

Programs from ZANE ProEd Academy that directly address the skill gaps discussed above.

Browse all pharmacovigilance courses →

Follow Zane ProEd on Google

Preferred Source

Add our publication as a preferred source to get the latest clinical research guides, industry updates, and career intel directly in your Google Top Stories & AI Overviews.

Add on Google